Opioid Dependence- Pipeline Insight, 2025
Description
DelveInsight’s, “Opioid Dependence- Pipeline Insight, 2025” report provides comprehensive insights about 35+ companies and 40+ pipeline drugs in Opioid Dependence pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Geography Covered
Opioid Dependence: Overview
Opioid dependence is a disorder of regulation of opioid use arising from repeated or continuous use of opioids. The characteristic feature of dependence is a strong internal drive to use opioids, which manifests itself by an impaired ability to control use, increasing priority given to use over other activities, and persistence in use despite harm or negative consequences.
Opioids can lead to physical dependence within a short time, as little as 4-8 weeks. In other words, the body will become used to opioids so that it has difficulty functioning without them. With chronic use, abruptly stopping opioid use leads to withdrawal symptoms, including generalized pain, chills, cramps, diarrhoea, dilated pupils, restlessness, anxiety, nausea, vomiting, insomnia, and very intense cravings. However, people do not die from opioid withdrawal. Because these symptoms are severe, it creates significant motivation to continue using opioids to prevent withdrawal.
Dependence is associated with withdrawal syndrome, which occurs upon cessation of repeated exposure to a drug stimulus. Providers must advise patients not to stop taking chronic opioids without first tapering their medication dosage. Dependence is also a subset of a substance use disorder, manifesting as physical or psychological dependence or both. Opioid withdrawal onset varies with the type of opioid used but correlates with dependence.
Chronic opioid use causes alterations in receptor sensitivity, leading to medication tolerance and changes in pain perception. Opioid-induced hyperalgesia (OIH) causes pain perception out of proportion to the stimulus (hyperalgesia) in those who use or misuse opioids long-term.
Opioids binds to the receptors within the CNS as well as throughout the peripheral tissues. These receptors are normally stimulated by endogenous peptides (endorphins, enkephalins, and dynorphins) produced in response to noxious stimulation. Action on these same receptors induces intense euphoria. This causes many individuals to continue using with the intention of recreating that first high. Most people who misuse opioids do so for pain relief or to prevent withdrawal symptoms.
The development of effective treatments for opioid dependence is of great importance given the devastating consequences of the disease. Counseling and behavioral therapies may be an important part of treatment alongside medications; however, they are effective by themselves. Medications are also used to relieve cravings, relieve withdrawal symptoms, and block the euphoric effects of opioids. These medications do not “cure” the disorder but rather improve safety and prevent withdrawal symptoms, which can lead to relapse or continued drug use.
""Opioid Dependence- Pipeline Insight, 2025"" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Opioid Dependence pipeline landscape is provided which includes the disease overview and Opioid Dependence treatment guidelines. The assessment part of the report embraces, in depth Opioid Dependence commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Opioid Dependence collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Report Highlights
This segment of the Opioid Dependence report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Opioid Dependence Emerging Drugs
Further product details are provided in the report……..
Opioid Dependence: Therapeutic Assessment
This segment of the report provides insights about the different Opioid Dependence drugs segregated based on following parameters that define the scope of the report, such as:
Opioid Dependence: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Opioid Dependence therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Opioid Dependence drugs.
Opioid Dependence Report Insights
Current Treatment Scenario and Emerging Therapies:
Geography Covered
- Global coverage
Opioid Dependence: Overview
Opioid dependence is a disorder of regulation of opioid use arising from repeated or continuous use of opioids. The characteristic feature of dependence is a strong internal drive to use opioids, which manifests itself by an impaired ability to control use, increasing priority given to use over other activities, and persistence in use despite harm or negative consequences.
Opioids can lead to physical dependence within a short time, as little as 4-8 weeks. In other words, the body will become used to opioids so that it has difficulty functioning without them. With chronic use, abruptly stopping opioid use leads to withdrawal symptoms, including generalized pain, chills, cramps, diarrhoea, dilated pupils, restlessness, anxiety, nausea, vomiting, insomnia, and very intense cravings. However, people do not die from opioid withdrawal. Because these symptoms are severe, it creates significant motivation to continue using opioids to prevent withdrawal.
Dependence is associated with withdrawal syndrome, which occurs upon cessation of repeated exposure to a drug stimulus. Providers must advise patients not to stop taking chronic opioids without first tapering their medication dosage. Dependence is also a subset of a substance use disorder, manifesting as physical or psychological dependence or both. Opioid withdrawal onset varies with the type of opioid used but correlates with dependence.
Chronic opioid use causes alterations in receptor sensitivity, leading to medication tolerance and changes in pain perception. Opioid-induced hyperalgesia (OIH) causes pain perception out of proportion to the stimulus (hyperalgesia) in those who use or misuse opioids long-term.
Opioids binds to the receptors within the CNS as well as throughout the peripheral tissues. These receptors are normally stimulated by endogenous peptides (endorphins, enkephalins, and dynorphins) produced in response to noxious stimulation. Action on these same receptors induces intense euphoria. This causes many individuals to continue using with the intention of recreating that first high. Most people who misuse opioids do so for pain relief or to prevent withdrawal symptoms.
The development of effective treatments for opioid dependence is of great importance given the devastating consequences of the disease. Counseling and behavioral therapies may be an important part of treatment alongside medications; however, they are effective by themselves. Medications are also used to relieve cravings, relieve withdrawal symptoms, and block the euphoric effects of opioids. These medications do not “cure” the disorder but rather improve safety and prevent withdrawal symptoms, which can lead to relapse or continued drug use.
""Opioid Dependence- Pipeline Insight, 2025"" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Opioid Dependence pipeline landscape is provided which includes the disease overview and Opioid Dependence treatment guidelines. The assessment part of the report embraces, in depth Opioid Dependence commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Opioid Dependence collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Report Highlights
- The companies and academics are working to assess challenges and seek opportunities that could influence Opioid Dependence R&D. The therapies under development are focused on novel approaches to treat/improve Opioid Dependence.
This segment of the Opioid Dependence report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Opioid Dependence Emerging Drugs
- OX 124: Orexo
- APH-1501: Aphios
- DMX-1002: DemeRx IB, Inc.
- Noribogaine: DemeRx IB, Inc.
Further product details are provided in the report……..
Opioid Dependence: Therapeutic Assessment
This segment of the report provides insights about the different Opioid Dependence drugs segregated based on following parameters that define the scope of the report, such as:
- Major Players in Opioid Dependence
- There are approx. 35+ key companies which are developing the therapies for Opioid Dependence. The companies which have their Opioid Dependence drug candidates in the most advanced stage, i.e. Preregistration Phase include, Orexo.
- Phases
- Late stage products (Phase III)
- Mid-stage products (Phase II)
- Early-stage product (Phase I) along with the details of
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates
- Route of Administration
- Oral
- Intravenous
- Subcutaneous
- Parenteral
- Topical
- Molecule Type
- Recombinant fusion proteins
- Small molecule
- Monoclonal antibody
- Peptide
- Polymer
- Gene therapy
- Product Type
Opioid Dependence: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Opioid Dependence therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Opioid Dependence drugs.
Opioid Dependence Report Insights
- Opioid Dependence Pipeline Analysis
- Therapeutic Assessment
- Unmet Needs
- Impact of Drugs
- Pipeline Product Profiles
- Therapeutic Assessment
- Pipeline Assessment
- Inactive drugs assessment
- Unmet Needs
Current Treatment Scenario and Emerging Therapies:
- How many companies are developing Opioid Dependence drugs?
- How many Opioid Dependence drugs are developed by each company?
- How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Opioid Dependence?
- What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Opioid Dependence therapeutics?
- What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
- What are the clinical studies going on for Opioid Dependence and their status?
- What are the key designations that have been granted to the emerging drugs?
- Opiant Pharmaceuticals
- Orexo
- Aphios Pharma
- DemeRx IB, Inc.
- Alar Pharmaceuticals
- BioXcel Therapeutics
- Lyndra Therapeutics
- Trevena
- Aptinyx
- Indivior
- Cerevel Therapeutics
- BioCorRx
- Delpor
- AstraZeneca
- Gilgamesh Pharmaceuticals
- OPNT-003
- OX 124
- APH 1501
- DMX-1002
- ALA-1000
- BXCL501
- LYN 014
- TRV-734
- NYX-783
- INDV-2000
- CVL-354
- BICX104
- DLP-160
- AZD-4041
- GM-300X
Table of Contents
80 Pages
- Introduction
- Executive Summary
- Opioid Dependence: Overview
- Causes
- Mechanism of Action
- Signs and Symptoms
- Diagnosis
- Disease Management
- Pipeline Therapeutics
- Comparative Analysis
- Therapeutic Assessment
- Assessment by Product Type
- Assessment by Stage and Product Type
- Assessment by Route of Administration
- Assessment by Stage and Route of Administration
- Assessment by Molecule Type
- Assessment by Stage and Molecule Type
- Opioid Dependence– DelveInsight’s Analytical Perspective
- Late Stage Products (Preregistration)
- Comparative Analysis
- OX 124: Orexo
- Product Description
- Research and Development
- Product Development Activities
- Drug profiles in the detailed report…..
- Mid Stage Products (Phase II)
- Comparative Analysis
- APH-1501: Aphios
- Product Description
- Research and Development
- Product Development Activities
- Drug profiles in the detailed report…..
- Early Stage Products (Phase I)
- Comparative Analysis
- Noribogaine: DemeRx IB, Inc.
- Product Description
- Research and Development
- Product Development Activities
- Drug profiles in the detailed report…..
- Preclinical and Discovery Stage Products
- Comparative Analysis
- GM-300X: Gilgamesh Pharmaceuticals
- Product Description
- Research and Development
- Product Development Activities
- Inactive Products
- Comparative Analysis
- Opioid Dependence Key Companies
- Opioid Dependence Key Products
- Opioid Dependence- Unmet Needs
- Opioid Dependence- Market Drivers and Barriers
- Opioid Dependence- Future Perspectives and Conclusion
- Opioid Dependence Analyst Views
- Opioid Dependence Key Companies
- Appendix
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
